Skip to main content
NAUT
NASDAQ Industrial Applications And Services

Perceptive Advisors Discloses 9.1% Stake in Nautilus Biotechnology

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.91
Mkt Cap
$113.512M
52W Low
$0.62
52W High
$4.31
52W Position info
47% above low
Off High info
79% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

NAUT sits 47% above its 52-week low of $0.62.

Summary

Perceptive Advisors disclosed a 9.1% stake in Nautilus Biotechnology, holding 11.6 million shares, a new position from a prominent biotech investor.


Key Events · Ownership and Investor Activity · NAUT

  • Perceptive Advisors Discloses 9.1% Stake

    Perceptive Advisors LLC and Joseph Edelman report aggregate beneficial ownership of 11,634,211 shares, representing 9.1% of Nautilus Biotechnology's common stock.

  • Holdings Breakdown

    Perceptive Life Sciences Master Fund directly holds 11,468,351 shares, and C2 Life Sciences LLC holds 165,860 shares. Perceptive Advisors serves as investment manager to both entities.

  • Stake Based on Recent Share Count

    The 9.1% ownership percentage is calculated using 127,255,223 shares outstanding as of July 24, 2026, as disclosed in Nautilus's 10-Q filed July 28, 2026.

  • New Position from Prominent Biotech Investor

    This is the first public disclosure of Perceptive's stake, following Andreessen Horowitz funds' reduction of their position in June 2026.


Analysis · NAUT · Industrial Applications And Services

A 9.1% stake in Nautilus Biotechnology has been disclosed by Perceptive Advisors, the healthcare-focused investment firm led by Joseph Edelman, amounting to 11.6 million shares. This is a significant new position from a sophisticated biotech investor, coming after Andreessen Horowitz funds reduced their stake in June. The filing reveals that Perceptive Life Sciences Master Fund holds 11.47 million shares and C2 Life Sciences holds 165,860 shares. The stake is based on 127.3 million shares outstanding as of July 24, 2026. This new ownership could signal confidence in Nautilus's technology despite the company's recent delay of its broadscale assay and first revenue only in Q2 2026.

How filings like this one have moved

In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NAUT was trading at $0.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $113.5M. The 52-week trading range was $0.62 to $4.31. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NAUT - Latest Insights

NAUT
Sep 11, 2026, 5:08 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $1.01
Real-time Price: $1.01 info
Change: $0 (0%) info
Market Cap: $129.8M info
NAUT
Aug 28, 2026, 7:43 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.890
Real-time Price: $1.01 info
Change: +$0.120 (+13%) info
Market Cap: $129.8M info
NAUT
Jul 28, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.20
Real-time Price: $1.01 info
Change: -$0.190 (-16%) info
Market Cap: $129.8M info
NAUT
Jul 28, 2026, 8:10 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.51
Real-time Price: $1.01 info
Change: -$0.500 (-33%) info
Market Cap: $129.8M info
NAUT
Jul 27, 2026, 7:29 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.72
Real-time Price: $1.01 info
Change: -$0.710 (-41%) info
Market Cap: $129.8M info